Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BICCS
2024-516849-39-01Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ceftazidime, piperacillin + tazobactam, cefepime, meropenem, ceftazidime + avibactam and 2 more in sepsis, hospital-acquired sepsis, bacterial disease and 1 more (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: 30-day all-cause mortality (CID vs IID). Planned start Nov 2024; status: authorised.
02
Drugs
ceftazidimepiperacillin + tazobactamcefepimemeropenemceftazidime + avibactam
03
Conditions
sepsishospital-acquired sepsisbacterial diseaseGram-negative bacterial infection
Beyond the preview
Go deeper on 2024-516849-39-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516849-39-01.